LaFleur & Godfrey LLC Increases Stock Position in Hologic, Inc. (NASDAQ:HOLX)

LaFleur & Godfrey LLC boosted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 130,373 shares of the medical equipment provider’s stock after purchasing an additional 3,655 shares during the quarter. Hologic comprises 1.3% of LaFleur & Godfrey LLC’s investment portfolio, making the stock its 28th largest holding. LaFleur & Godfrey LLC’s holdings in Hologic were worth $9,399,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Prentiss Smith & Co. Inc. lifted its position in Hologic by 0.3% in the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock valued at $3,967,000 after purchasing an additional 130 shares during the period. Covestor Ltd lifted its holdings in shares of Hologic by 23.8% in the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 133 shares during the period. First Horizon Advisors Inc. boosted its stake in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares in the last quarter. Brooklyn Investment Group boosted its stake in shares of Hologic by 14.7% in the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after buying an additional 145 shares in the last quarter. Finally, Empirical Finance LLC grew its holdings in Hologic by 1.8% during the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after acquiring an additional 147 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Ratings Changes

HOLX has been the topic of several research analyst reports. Royal Bank of Canada boosted their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. Jefferies Financial Group initiated coverage on shares of Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price for the company. JPMorgan Chase & Co. boosted their price target on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Evercore ISI lifted their price objective on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Finally, Mizuho lowered their target price on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Seven analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and an average price target of $88.92.

Hologic Trading Down 0.3 %

Shares of HOLX opened at $69.73 on Monday. Hologic, Inc. has a fifty-two week low of $68.61 and a fifty-two week high of $84.67. The company has a market capitalization of $15.82 billion, a PE ratio of 20.94, a price-to-earnings-growth ratio of 2.44 and a beta of 0.97. The stock has a fifty day moving average of $74.84 and a two-hundred day moving average of $78.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.89 earnings per share. As a group, analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.